TRCT
DFTX

Tower Research Capital (TRC)’s Definium Therapeutics DFTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Sell
6,308
-997
-14% -$24.6K 0.01% 1393
2026
Q1 		$138K Buy
7,305
+2,971
+69% +$50.4K ﹤0.01% 1921
2025
Q4 		$58K Buy
4,334
+1,884
+77% +$23.3K ﹤0.01% 2317
2025
Q3 		$28.9K Sell
2,450
-6,406
-72% -$59.7K ﹤0.01% 2971
2025
Q2 		$57.5K Sell
8,856
-2,512
-22% -$16.5K ﹤0.01% 2846
2025
Q1 		$66.5K Buy
11,368
+9,218
+429% +$66K ﹤0.01% 2019
2024
Q4 		$15K Sell
2,150
-1,895
-47% -$13K ﹤0.01% 3430
2024
Q3 		$23K Buy
4,045
+1,027
+34% +$7.14K ﹤0.01% 3166
2024
Q2 		$21.8K Sell
3,018
-2,745
-48% -$24K ﹤0.01% 3708
2024
Q1 		$54.2K Sell
5,763
-57
-1% -$325 ﹤0.01% 2220
2023
Q4 		$21.3K Buy
5,820
+5,687
+4,276% +$17.1K ﹤0.01% 3607
2023
Q3 		$416 Buy
+133
New +$547 ﹤0.01% 5571
2023
Q2 		– Sell
-3,103
Closed -$10K – 6249
2023
Q1 		$10K Buy
3,103
+1,792
+137% +$5.96K ﹤0.01% 4375
2022
Q4 		$3K Sell
1,311
-48
-4% -$133 ﹤0.01% 5212
2022
Q3 		$5K Buy
1,359
+123
+10% +$1.18K ﹤0.01% 5153
2022
Q2 		$12K Buy
1,236
+628
+103% +$7.95K ﹤0.01% 4290
2022
Q1 		$10K Sell
608
-66
-10% -$1.15K ﹤0.01% 4321
2021
Q4 		$14K Buy
674
+62
+10% +$1.98K ﹤0.01% 4086
2021
Q3 		$21K Sell
612
-4
-0.6% -$173 ﹤0.01% 3668
2021
Q2 		$32K Buy
+616
New +$32.3K ﹤0.01% 3425

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Tower Research Capital (TRC)'s DFTX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Definium Therapeutics (DFTX) stake by 14% in Q2 2026, selling an estimated $24.6K and leaving 6,308 shares worth $297K. The position accounts for 0.01% of the portfolio, ranked #1393.

Tower Research Capital (TRC) first reported a position in DFTX in Q2 2021 and has held it in 20 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Tower Research Capital (TRC) held 6,308 shares of Definium Therapeutics worth $297K as of Q2 2026.
  • Tower Research Capital (TRC) sold 997 Definium Therapeutics shares in Q2 2026, an estimated $24.6K.
  • Definium Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1393 holding.
  • Tower Research Capital (TRC) first reported a position in Definium Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.